Phase 3Not yet recruitingPriority 1 · Highest priorityNCT05700448
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Plain-language summary
This Phase 3 trial is comparing Sugemalimab, Placebo, and other medications against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Sugemalimab (BIOLOGICAL): IV infusion | Placebo (DRUG): IV infusion | Pegaspargase (DRUG): Intramuscular injection | Gemcitabine (DRUG): IV infusion | Oxaliplatin (DRUG): IV infusion
- Drugs / treatments
- Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details